ANIX VS JNJ Stock Comparison

PerformanceAnalyst Price TargetsSentimentTechnicalsEarningsProfitVolatilityDividend
PerformanceAnalyst Price TargetsSentimentTechnicalsEarningsProfitVolatilityDividend

Performance

ANIX
10/100

ANIX returned -42.05% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

JNJ
73/100

JNJ returned -15.84% in the last 12 months. Based on SPY's performance of -20.60%, its performance is above average giving it a score of 73 of 100.

Analyst Price Targets

ANIX
75/100

1 analysts offer 12-month price targets for ANIX. Together, they have an average target of 8, the most optimistic target put ANIX at 8 within 12-months and the most pessimistic has ANIX at 8.

JNJ
63/100

23 analysts offer 12-month price targets for JNJ. Together, they have an average target of 176.5, the most optimistic target put JNJ at 205 within 12-months and the most pessimistic has JNJ at 90.

Sentiment

ANIX
67/100

ANIX had a bullish sentiment score of 66.58% across Twitter and StockTwits over the last 12 months. It had an average of 1.57 posts, 0.29 comments, and 1.43 likes per day.

JNJ
72/100

JNJ had a bullish sentiment score of 71.87% across Twitter and StockTwits over the last 12 months. It had an average of 205.31 posts, 3,341.61 comments, and 16,552.61 likes per day.

Technicals

ANIX
11/100

ANIX receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

JNJ
14/100

JNJ receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

Earnings

ANIX
61/100

ANIX has missed earnings 3 times in the last 20 quarters.

JNJ
100/100

JNJ has missed earnings 0 times in the last 20 quarters.

Profit

ANIX
10/100

Out of the last 20 quarters, ANIX has had 0 profitable quarters and has increased their profits year over year on 0 of them.

JNJ
74/100

Out of the last 20 quarters, JNJ has had 19 profitable quarters and has increased their profits year over year on 9 of them.

Volatility

ANIX
34/100

ANIX has had a lower than average amount of volatility over the last 12 months giving it a score of 34 of 100.

JNJ
43/100

JNJ has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.

Dividend

ANIX

"Dividend" not found for ANIX

JNJ
100/100

JNJ's most recent dividend was $0.90 per share, based on a share price of $145.60. It was a payout ratio of 61.39% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

Anixa Biosciences, Inc. Summary

Nasdaq / ANIX
Healthcare
Biotechnology
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Johnson & Johnson Summary

New York Stock Exchange / JNJ
Healthcare
Drug Manufacturers - General
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.